MEI Pharma (NASDAQ:MEIP – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.48) EPS for the quarter, Zacks reports.
MEI Pharma Stock Performance
Shares of MEIP traded down $0.04 during midday trading on Wednesday, hitting $2.66. The company had a trading volume of 2,534 shares, compared to its average volume of 11,683. The company’s 50-day simple moving average is $2.68 and its 200-day simple moving average is $2.90. MEI Pharma has a 1 year low of $2.30 and a 1 year high of $4.90. The firm has a market capitalization of $17.72 million, a P/E ratio of -0.38 and a beta of 0.79.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on shares of MEI Pharma in a report on Tuesday. They set a “buy” rating for the company.
MEI Pharma Company Profile
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Recommended Stories
- Five stocks we like better than MEI Pharma
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Inflation Persists, But So Do Stock Opportunities: Rally On
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.